Wedbush maintains IDEAYA Biosciences at Outperform, raises price target to $63 from $60

What happened

Wedbush maintained its Outperform rating on IDEAYA Biosciences and raised its price target to $63 from $60, a 5.0% increase. The new target implies 101.1% upside from the stock’s Nov. 3 closing price of $31.33.

Confirmed

Global impact / market context

The higher target signals that Wedbush sees more potential value in IDEAYA shares while keeping its positive rating. If investors act on that view, buying could support the share price; however, the article gives no new company results or business developments to explain the change.

Analyst inference

This is an analyst opinion update, not a reported change in IDEAYA’s operations, revenue, costs, or cash available. The stated 101.1% upside compares the target with one past closing price and does not establish that the shares will reach that level.

Analyst inference

What to watch

1. Watch for IDEAYA company updates on revenue, costs, or research progress, since the article provides no business results to support Wedbush’s higher target. Analyst inference
2. Check whether other analyst ratings or price targets change; broader agreement or disagreement could influence investor positioning, meaning how investors choose to hold the shares. Analyst inference
3. Compare the share price with Wedbush’s $63 target over time, while remembering that the target is an analyst estimate rather than a guaranteed future price. Analyst inference

Evidence

• Original source link unavailable